
Opinion|Videos|July 12, 2024
PERSEUS Trial Findings at EHA 2024
Joseph Mikhael, MD, discusses the PERSEUS trial findings presented at EHA 2024.
Advertisement
Episodes in this series

Video content above is prompted by the following:
- Discuss the data presented at the European Hematology Association 2024 (EHA 2024) Hybrid Congress on minimal residual disease (MRD) in the PERSEUS trial of daratumumab plus bortezomib, lenalidomide, and dexamethasone (D-VRd) induction/consolidation followed by daratumumab/lenalidomide (D-R) in patients with newly diagnosed multiple myeloma.
- What was the objective of this study?
- How was this study designed/what methodology was used?
- What results were presented?
- Please provide your key takeaways from this study. How might these findings impact the management of patients with multiple myeloma?
- How have the criteria for multiple myeloma patients to be considered transplant-eligible or -ineligible evolved in recent history? How do you evaluate transplant eligibility in your practice?
Advertisement
Related to this article

Real-world acne treatment adherence spans 6% to 84%, with cost, adverse effects, and slow results driving nonadherence.

A value-based care pilot within Kentucky’s Medicaid program reduced total costs for adults with substance use disorder while improving utilization of evidence-based treatments.

A scalable, symptom-focused patient education model paired with coordinated podiatric care offers managed care organizations a low-barrier strategy to reduce diabetic foot ulcers and costly amputations.

Pimicotinib, a once-daily oral CSF-1R inhibitor, is now FDA approved for adults with TGCT for whom surgery may worsen function or cause severe morbidity.

Pooled real-world data show an 88% response rate with brexu-cel in relapsed mantle cell lymphoma (MCL), but cost and QOL data are scarce.

Employer diabetes guide; Camden psychedelic therapy input; CRC after EMR; rural HFrEF care; JAMA obesity report.

This article analyzes gaps in US biosimilar development, quantifies market opportunities, and proposes policy and economic solutions to improve cost savings and patient access.
Advertisement
Advertisement
Trending on AJMC
1
Health Equity & Access Weekly Roundup: November 20, 2026
2
FDA Approves Pimicotinib for Symptomatic Tenosynovial Giant Cell Tumor
3
Defining High-Efficacy MS Therapy: Access, Formularies, and Patient Choice
4
Four Ways to Boost Awareness, Access for COVID-19 PEP
5

